The FDA has cleared Allergan’s Xen glaucoma treatment system which consists of the Xen45 gel stent and the Xen injector.

The Xen glaucoma treatment system reduces inner eye pressure in patients and is indicated for the management of refractory glaucoma, where previous surgical treatment has failed.

The device is implanted through an ab interno approach (cornea incision and vasodilation of the Schlemm canal and then the targeted tissue is disrupted and disintegrated by applying heat energy in bursts with a high-peak power and low duty cycle) and reduces inner eye pressure by creating a new drainage channel with a permanent implant that becomes flexible. — Cynthia Jessup